 | • レポートコード：MRC23Q35755 • 出版社/出版日：QYResearch / 2023年3月 • レポート形態：英文、PDF、94ページ • 納品方法：Eメール（2-3日） • 産業分類：医薬品 |
| Single User | ￥435,000 (USD2,900) | ▷ お問い合わせ |
| Enterprise License | ￥870,000 (USD5,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本調査レポートは世界のアドレナリン受容体遮断薬市場について調査・分析し、世界のアドレナリン受容体遮断薬市場概要、市場トレンド、主要企業別競争状況、タイプ別セグメント分析（アルファブロッカー、ベータブロッカー、その他）、用途別セグメント分析（心臓病、高血圧、その他）、地域別市場規模、主要企業のプロファイルなどに関する情報を掲載しています。主要企業としては、Pfizer、Prometheus Laboratories、Baxter、Novartis、AstraZeneca Pharmaceuticals、Sanofi、Novitium Pharma、Sun Pharmaceutical Industries、Granules、Mylanなどが含まれています。世界のアドレナリン受容体遮断薬市場は、2022年にXXX米ドル、2029年にはXXX米ドルに達すると予測され、予測期間の年平均成長率はXXX％です。COVID-19とロシア・ウクライナ戦争の影響は、アドレナリン受容体遮断薬市場規模を推定する際に考慮しました。本レポートは、アドレナリン受容体遮断薬の世界市場を定量的・定性的な分析により包括的に提示し、読者がビジネス/成長戦略を策定し、市場競争状況を把握し、現在の市場における自社のポジションを分析し、アドレナリン受容体遮断薬に関するビジネス上の意思決定に役立てることを目的としています。 ・アドレナリン受容体遮断薬市場の概要 - アドレナリン受容体遮断薬のタイプ別セグメント - 世界のアドレナリン受容体遮断薬市場規模：タイプ別分析（アルファブロッカー、ベータブロッカー、その他） - アドレナリン受容体遮断薬の用途別セグメント - 世界のアドレナリン受容体遮断薬市場規模：用途別分析（心臓病、高血圧、その他） - 世界のアドレナリン受容体遮断薬市場規模予測（2018年-2029年） ・アドレナリン受容体遮断薬市場の成長トレンド - アドレナリン受容体遮断薬の地域別市場規模（2018年-2029年） - アドレナリン受容体遮断薬市場ダイナミクス - アドレナリン受容体遮断薬の業界動向 - アドレナリン受容体遮断薬市場の成長ドライバ、課題、阻害要因 ・主要企業別競争状況 - 企業別市場シェア - 世界の主要企業、業界ランキング分析 - 市場への参入、M＆A動向 ・タイプ別セグメント：アルファブロッカー、ベータブロッカー、その他 - 世界のアドレナリン受容体遮断薬のタイプ別市場規模（2018年-2023年） - 世界のアドレナリン受容体遮断薬のタイプ別市場規模（2024年-2029年） ・用途別セグメント：心臓病、高血圧、その他 - 世界のアドレナリン受容体遮断薬の用途別市場規模（2018年-2023年） - 世界のアドレナリン受容体遮断薬の用途別市場規模（2024年-2029年） ・アドレナリン受容体遮断薬の地域別市場規模 - 北米のアドレナリン受容体遮断薬市場規模（2018年-2029年） - アメリカのアドレナリン受容体遮断薬市場規模（2018年-2029年） - ヨーロッパのアドレナリン受容体遮断薬市場規模（2018年-2029年） - アジア太平洋のアドレナリン受容体遮断薬市場規模（2018年-2029年） - 中国のアドレナリン受容体遮断薬市場規模（2018年-2029年） - 日本のアドレナリン受容体遮断薬市場規模（2018年-2029年） - 韓国のアドレナリン受容体遮断薬市場規模（2018年-2029年） - インドのアドレナリン受容体遮断薬市場規模（2018年-2029年） - オーストラリアのアドレナリン受容体遮断薬市場規模（2018年-2029年） - 中南米のアドレナリン受容体遮断薬市場規模（2018年-2029年） - 中東・アフリカのアドレナリン受容体遮断薬市場規模（2018年-2029年） ・主要企業のプロファイル：企業情報、事業概要、売上、動向 Pfizer、Prometheus Laboratories、Baxter、Novartis、AstraZeneca Pharmaceuticals、Sanofi、Novitium Pharma、Sun Pharmaceutical Industries、Granules、Mylan ・アナリストの観点/結論 ・調査方法とデータソース |
Adrenoceptor Blocking Drugs Block Adrenergic Receptors and Thus Antagonize the Action of Noradrenergic Neurotransmitters or Adrenergic Receptor Agonists. in Whole Animals, the Strength of Their Action Depends on the Noradrenergic Tone of the Body.
Highlights
The global Adrenoceptor Blocking Drugs market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
North American market for Adrenoceptor Blocking Drugs is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
Asia-Pacific market for Adrenoceptor Blocking Drugs is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The global market for Adrenoceptor Blocking Drugs in Heart Disease is estimated to increase from $ million in 2023 to $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The key global companies of Adrenoceptor Blocking Drugs include Pfizer, Prometheus Laboratories, Baxter, Novartis, AstraZeneca Pharmaceuticals, Sanofi, Novitium Pharma, Sun Pharmaceutical Industries and Granules, etc. In 2022, the world’s top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Adrenoceptor Blocking Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Adrenoceptor Blocking Drugs.
The Adrenoceptor Blocking Drugs market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Adrenoceptor Blocking Drugs market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Adrenoceptor Blocking Drugs companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.
By Company
Pfizer
Prometheus Laboratories
Baxter
Novartis
AstraZeneca Pharmaceuticals
Sanofi
Novitium Pharma
Sun Pharmaceutical Industries
Granules
Mylan
Segment by Type
Alpha Blockers
Beta Blockers
Others
Segment by Application
Heart Disease
Hypertension
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Adrenoceptor Blocking Drugs companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Adrenoceptor Blocking Drugs Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Alpha Blockers
1.2.3 Beta Blockers
1.2.4 Others
1.3 Market by Application
1.3.1 Global Adrenoceptor Blocking Drugs Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Heart Disease
1.3.3 Hypertension
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Adrenoceptor Blocking Drugs Market Perspective (2018-2029)
2.2 Adrenoceptor Blocking Drugs Growth Trends by Region
2.2.1 Global Adrenoceptor Blocking Drugs Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Adrenoceptor Blocking Drugs Historic Market Size by Region (2018-2023)
2.2.3 Adrenoceptor Blocking Drugs Forecasted Market Size by Region (2024-2029)
2.3 Adrenoceptor Blocking Drugs Market Dynamics
2.3.1 Adrenoceptor Blocking Drugs Industry Trends
2.3.2 Adrenoceptor Blocking Drugs Market Drivers
2.3.3 Adrenoceptor Blocking Drugs Market Challenges
2.3.4 Adrenoceptor Blocking Drugs Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Adrenoceptor Blocking Drugs Players by Revenue
3.1.1 Global Top Adrenoceptor Blocking Drugs Players by Revenue (2018-2023)
3.1.2 Global Adrenoceptor Blocking Drugs Revenue Market Share by Players (2018-2023)
3.2 Global Adrenoceptor Blocking Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Adrenoceptor Blocking Drugs Revenue
3.4 Global Adrenoceptor Blocking Drugs Market Concentration Ratio
3.4.1 Global Adrenoceptor Blocking Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Adrenoceptor Blocking Drugs Revenue in 2022
3.5 Adrenoceptor Blocking Drugs Key Players Head office and Area Served
3.6 Key Players Adrenoceptor Blocking Drugs Product Solution and Service
3.7 Date of Enter into Adrenoceptor Blocking Drugs Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Adrenoceptor Blocking Drugs Breakdown Data by Type
4.1 Global Adrenoceptor Blocking Drugs Historic Market Size by Type (2018-2023)
4.2 Global Adrenoceptor Blocking Drugs Forecasted Market Size by Type (2024-2029)
5 Adrenoceptor Blocking Drugs Breakdown Data by Application
5.1 Global Adrenoceptor Blocking Drugs Historic Market Size by Application (2018-2023)
5.2 Global Adrenoceptor Blocking Drugs Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Adrenoceptor Blocking Drugs Market Size (2018-2029)
6.2 North America Adrenoceptor Blocking Drugs Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Adrenoceptor Blocking Drugs Market Size by Country (2018-2023)
6.4 North America Adrenoceptor Blocking Drugs Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Adrenoceptor Blocking Drugs Market Size (2018-2029)
7.2 Europe Adrenoceptor Blocking Drugs Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Adrenoceptor Blocking Drugs Market Size by Country (2018-2023)
7.4 Europe Adrenoceptor Blocking Drugs Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Adrenoceptor Blocking Drugs Market Size (2018-2029)
8.2 Asia-Pacific Adrenoceptor Blocking Drugs Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Adrenoceptor Blocking Drugs Market Size by Region (2018-2023)
8.4 Asia-Pacific Adrenoceptor Blocking Drugs Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Adrenoceptor Blocking Drugs Market Size (2018-2029)
9.2 Latin America Adrenoceptor Blocking Drugs Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Adrenoceptor Blocking Drugs Market Size by Country (2018-2023)
9.4 Latin America Adrenoceptor Blocking Drugs Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Adrenoceptor Blocking Drugs Market Size (2018-2029)
10.2 Middle East & Africa Adrenoceptor Blocking Drugs Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Adrenoceptor Blocking Drugs Market Size by Country (2018-2023)
10.4 Middle East & Africa Adrenoceptor Blocking Drugs Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Pfizer
11.1.1 Pfizer Company Detail
11.1.2 Pfizer Business Overview
11.1.3 Pfizer Adrenoceptor Blocking Drugs Introduction
11.1.4 Pfizer Revenue in Adrenoceptor Blocking Drugs Business (2018-2023)
11.1.5 Pfizer Recent Development
11.2 Prometheus Laboratories
11.2.1 Prometheus Laboratories Company Detail
11.2.2 Prometheus Laboratories Business Overview
11.2.3 Prometheus Laboratories Adrenoceptor Blocking Drugs Introduction
11.2.4 Prometheus Laboratories Revenue in Adrenoceptor Blocking Drugs Business (2018-2023)
11.2.5 Prometheus Laboratories Recent Development
11.3 Baxter
11.3.1 Baxter Company Detail
11.3.2 Baxter Business Overview
11.3.3 Baxter Adrenoceptor Blocking Drugs Introduction
11.3.4 Baxter Revenue in Adrenoceptor Blocking Drugs Business (2018-2023)
11.3.5 Baxter Recent Development
11.4 Novartis
11.4.1 Novartis Company Detail
11.4.2 Novartis Business Overview
11.4.3 Novartis Adrenoceptor Blocking Drugs Introduction
11.4.4 Novartis Revenue in Adrenoceptor Blocking Drugs Business (2018-2023)
11.4.5 Novartis Recent Development
11.5 AstraZeneca Pharmaceuticals
11.5.1 AstraZeneca Pharmaceuticals Company Detail
11.5.2 AstraZeneca Pharmaceuticals Business Overview
11.5.3 AstraZeneca Pharmaceuticals Adrenoceptor Blocking Drugs Introduction
11.5.4 AstraZeneca Pharmaceuticals Revenue in Adrenoceptor Blocking Drugs Business (2018-2023)
11.5.5 AstraZeneca Pharmaceuticals Recent Development
11.6 Sanofi
11.6.1 Sanofi Company Detail
11.6.2 Sanofi Business Overview
11.6.3 Sanofi Adrenoceptor Blocking Drugs Introduction
11.6.4 Sanofi Revenue in Adrenoceptor Blocking Drugs Business (2018-2023)
11.6.5 Sanofi Recent Development
11.7 Novitium Pharma
11.7.1 Novitium Pharma Company Detail
11.7.2 Novitium Pharma Business Overview
11.7.3 Novitium Pharma Adrenoceptor Blocking Drugs Introduction
11.7.4 Novitium Pharma Revenue in Adrenoceptor Blocking Drugs Business (2018-2023)
11.7.5 Novitium Pharma Recent Development
11.8 Sun Pharmaceutical Industries
11.8.1 Sun Pharmaceutical Industries Company Detail
11.8.2 Sun Pharmaceutical Industries Business Overview
11.8.3 Sun Pharmaceutical Industries Adrenoceptor Blocking Drugs Introduction
11.8.4 Sun Pharmaceutical Industries Revenue in Adrenoceptor Blocking Drugs Business (2018-2023)
11.8.5 Sun Pharmaceutical Industries Recent Development
11.9 Granules
11.9.1 Granules Company Detail
11.9.2 Granules Business Overview
11.9.3 Granules Adrenoceptor Blocking Drugs Introduction
11.9.4 Granules Revenue in Adrenoceptor Blocking Drugs Business (2018-2023)
11.9.5 Granules Recent Development
11.10 Mylan
11.10.1 Mylan Company Detail
11.10.2 Mylan Business Overview
11.10.3 Mylan Adrenoceptor Blocking Drugs Introduction
11.10.4 Mylan Revenue in Adrenoceptor Blocking Drugs Business (2018-2023)
11.10.5 Mylan Recent Development
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details